Reta glucagon-like peptide-1 (GLP-1) receptor agonists offer a groundbreaking strategy to diabetes management. These innovative therapies function by mimicking the natural actions of GLP-1, a hormone secreted by the gut in response to food. By triggering GLP-1 receptors in the pancreas, these agents increase insulin release and reduce glucagon rele

The burgeoning landscape of innovative treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a comparable therapeutic goal – improving glycemic control and promoting substantial weight reduction – they exhibit intriguing differenc